As the COVID-19 pandemic and the search for an effective preventative vaccine continues, the Serum Institute of India has entered into manufacturing agreements with both Novavax and Codagenix to help supply their experimental COVID-19 vaccine candidates.
CDX-005, an intranasal, live-attenuated vaccine candidate, has completed preclinical animal studies, and Codagenix expects to initiate human trials by end of 2020.